Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

343
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
343
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026
Same author

Understanding what surgical advanced practice providers want: A survey of autonomy, tasks, and training preferences across three institutions.

American journal of surgery·2026
Same author

Updates to Early Detection of Prostate Cancer: AUA/SUO Guideline (2026).

The Journal of urology·2026
Same author

Digital pathology-based artificial intelligence algorithms in prostate cancer: inside the 'black box'.

BJU international·2026
Same author

Real-World Utility of Cxbladder Triage for Patients with Microhematuria: A Matched Cohort Study.

Urology practice·2026
Same author

Distinct Metabolomic Alterations Are Associated With Physical Function, Weight Loss, and Muscle Mass in Men With Cancer.

Journal of cachexia, sarcopenia and muscle·2026
Same journal

WHO Issues Guidelines for Treating Ebola and Marburg Viruses.

JAMA·2026
Same journal

FDA Approves Additional Naloxone Nasal Spray for Opioid Overdose.

JAMA·2026
Same journal

HIV May Hide in More Cells Than Previously Thought-Here's What That Could Mean for a Cure.

JAMA·2026
Same journal

US Dietary Supplement Use Increasing, Especially in Older Adults.

JAMA·2026
Same journal

Heat Stress From Climate Change Surges Globally.

JAMA·2026
Same journal

Strength Training Linked With Lower Cardiovascular Disease Risk in Women.

JAMA·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.7K

Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.

Lisa F Newcomb1,2, Jeannette M Schenk1, Yingye Zheng3

  • 1Cancer Prevention Program, Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.

JAMA
|May 30, 2024
PubMed
Summary
This summary is machine-generated.

Active surveillance for favorable-risk prostate cancer is effective, with 49% of men remaining progression-free at 10 years. This management strategy shows low rates of metastasis and prostate cancer mortality.

More Related Videos

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

7.8K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

Related Experiment Videos

Last Updated: Jun 25, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.7K
Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

7.8K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

Area of Science:

  • Urology
  • Oncology
  • Clinical Research

Background:

  • Protocol-directed active surveillance is crucial for managing favorable-risk prostate cancer.
  • Long-term oncological outcomes data are needed to inform clinical decision-making.

Purpose of the Study:

  • To evaluate the long-term oncological outcomes of patients undergoing active surveillance for favorable-risk prostate cancer.
  • To characterize outcomes in a multicenter, protocol-directed cohort.

Main Methods:

  • Prospective cohort study (Canary Prostate Active Surveillance Study) initiated in 2008.
  • Enrolled 2155 men with favorable-risk prostate cancer across 10 North American centers.
  • Follow-up through August 2022, assessing outcomes like biopsy reclassification, treatment, metastasis, and mortality.

Main Results:

  • At 10 years, 49% of patients remained free of progression or treatment.
  • Incidence of biopsy grade reclassification was 43%; treatment incidence was 49%.
  • Metastatic cancer occurred in 1.4% and prostate cancer mortality in 0.1% at 10 years.

Conclusions:

  • Active surveillance is an effective management strategy for favorable-risk prostate cancer.
  • Late progression or treatment during surveillance did not correlate with worse outcomes.
  • Study supports active surveillance for select prostate cancer patients.